PSA monitoring on TRT generates more anxiety than almost any other lab value. Men see the number rise from 0.8 to 1.4 and assume the worst. Meanwhile, the clinical reality is more nuanced: testosterone replacement causes predictable, modest PSA increases that are usually benign — but the monitoring matters because the rare exception can be clinically significant.
How TRT Affects PSA
PSA (prostate-specific antigen) is produced by prostate epithelial cells. Testosterone — and more specifically, its metabolite DHT — stimulates prostate tissue growth and PSA production. When a man starts TRT, his prostate responds to the higher androgen levels by increasing PSA output.
Typical PSA changes on TRT:
- First 3–6 months: PSA commonly increases by 0.3–0.5 ng/mL as the prostate responds to the new hormonal environment.
- 6–12 months: PSA typically stabilizes at the new level. The initial rise plateaus.
- Beyond 12 months: PSA should remain relatively stable. Continued rapid rises after stabilization warrant investigation.
The important reassurance: multiple large studies (including the TRAVERSE trial) have not shown that TRT increases prostate cancer incidence. The initial PSA rise reflects normal prostate tissue response to androgens, not malignant transformation.
PSA Velocity: The Number That Matters
A single PSA value is far less informative than the rate of change over time. PSA velocity — measured in ng/mL per year — is the metric that drives clinical decision-making:
| PSA Velocity | Interpretation | Action |
|---|---|---|
| < 0.35 ng/mL/year | Normal for men on TRT | Continue routine monitoring |
| 0.35–0.75 ng/mL/year | Elevated but may be TRT-related | Recheck in 3 months; discuss with prescriber |
| > 0.75 ng/mL/year | Concerning — independent of TRT effects | Urology referral for evaluation |
Velocity requires at least two measurements separated by time — ideally 6–12 months apart. This is why baseline PSA before starting TRT is essential: without it, you can't calculate velocity accurately.
The Finasteride Complication
Finasteride (1mg daily for hair loss or 5mg for BPH) reduces PSA levels by approximately 50% by blocking the conversion of testosterone to DHT. For men on both TRT and finasteride, PSA readings must be doubled to approximate the true value.
If a man on finasteride has a PSA of 1.5 ng/mL, his adjusted PSA is approximately 3.0 ng/mL. This adjusted value is what should be tracked for velocity calculations and clinical decision-making. Many clinicians unfamiliar with this interaction fail to make the adjustment, potentially missing meaningful elevations.
Communication is critical: Every provider who monitors your PSA needs to know you're on finasteride. The lab report won't flag the adjustment — it requires the clinician to know your medication list and apply the correction manually.
When to Involve Urology
Urology Referral Triggers
- PSA velocity > 0.75 ng/mL/year (adjusted for finasteride if applicable)
- Absolute PSA above 4.0 ng/mL (age-adjusted; lower thresholds apply for younger men)
- Sudden PSA jump: An increase of >1.0 ng/mL between two consecutive measurements warrants immediate evaluation
- Urinary symptoms: New or worsening urinary obstruction, frequency, or hematuria alongside rising PSA
- Family history: First-degree relative with prostate cancer lowers all thresholds
The Bottom Line
Track Velocity, Not Panic at Single Values
PSA monitoring on TRT is mandatory but shouldn't be anxiety-inducing. An initial rise of 0.3–0.5 ng/mL is expected and benign. What matters is velocity — the rate of change over time. Establish baseline before TRT, monitor every 6–12 months, adjust for finasteride, and involve urology when velocity exceeds evidence-based thresholds. The goal is vigilance without unnecessary alarm.